;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Brilacidin: Phase IIb ongoing

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin (formerly PMX-30063) Business: Infectious Molecular target: NA Description: Synthetic defensin mimetic bactericidal antibiotic Indication: Treat acute …

    Published on 7/14/2014
  • CHS-0214: Phase III started

    Coherus BioSciences Inc., Redwood City, Calif. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: CHS-0214 Business: Autoimmune Molecular target: Tumor …

    Published on 7/14/2014
  • CMX-2043: Phase IIa started

    Ischemix Inc., Maynard, Mass. Product: CMX-2043 Business: Cardiovascular Molecular target: Protein kinase B (PKB) (PKBA) (AKT) (AKT1) Description: Small molecule that modulates the protein kinase B (PKB; PKBA; AKT; AKT1…

    Published on 7/14/2014
  • CO-1686: Phase II started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Product: CO-1686, AVL-301 Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Small …

    Published on 7/14/2014
  • Diazoxide choline controlled release: Phase I started

    Essentialis Inc., Carlsbad, Calif. Product: Diazoxide choline controlled release (DCCR) Business: Endocrine/Metabolic Molecular target: ATP-dependent potassium channel (KATP) Description: ATP-dependent potassium channel…

    Published on 7/14/2014
  • Eltrombopag: Phase III started

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eltrombopag (Promacta, Revolade) Business: Cancer Molecular target: Thrombopoietin (TPO) …

    Published on 7/14/2014
  • Eye-D insert: Phase I/IIa started

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Eye-D insert Business: Ophthalmic Molecular target: NA Description: Intraocular controlled-release insert containing latanoprost, a prostaglandin …

    Published on 7/14/2014
  • FBP vaccine: Completed Phase IIa enrollment

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: FBP vaccine (GALE-301) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP) vaccine Indication: …

    Published on 7/14/2014
  • GFT505: Phase IIb ongoing

    Genfit S.A. (Euronext:GNFT), Loos, France Product: GFT505 Business: Hepatic Molecular target: Peroxisome proliferation activated receptor (PPAR) Description: Dual peroxisome proliferation activated receptor (PPAR) alpha…

    Published on 7/14/2014
  • GLPG1690: Phase I started

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: GLPG1690 Business: Pulmonary Molecular target: NA Description: Undisclosed compound Indication: …

    Published on 7/14/2014
  • Glycoconjugate ExPEC vaccine: Phase I started

    GlycoVaxyn AG, Schlieren, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Glycoconjugate ExPEC vaccine Business: Infectious Molecular target: NA Description: Bioconjugate vaccine against extra-…

    Published on 7/14/2014
  • ItMSCs: Phase IIa started

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: ItMSCs Business: Cardiovascular Molecular target: NA Description: Transplanted ischemic-tolerant mesenchymal stem cells Indication: Treat chronic heart …

    Published on 7/14/2014
  • Ladostigil: Phase IIb ongoing

    Avraham Pharmaceuticals Ltd., Yavneh, Israel Product: Ladostigil Business: Neurology Molecular target: NA Description: Cholinesterase, brain-selective monoamine oxidase inhibitor and neuroprotective agent Indication: …

    Published on 7/14/2014
  • MIN-117: Development discontinued

    Minerva Neurosciences Inc. (NASDAQ:NERV), Cambridge, Mass. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: MIN-117, Wf-516 Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Serotonin…

    Published on 7/14/2014
  • Optina danazol: Completed Phase IIb enrollment

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Product: Optina danazol Business: Ophthalmic Molecular target: NA Description: Ultra-low dose formulation of danazol, a derivative of the synthetic …

    Published on 7/14/2014
  • Oral CR845: Phase I started

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Maruishi Pharmaceutical Co. Ltd., Osaka, Japan Product: Oral CR845 Business: Neurology Molecular …

    Published on 7/14/2014
  • Pacritinib: Completed Phase III enrollment

    CTI BioPharma Corp. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Pacritinib (SB1518, ONX 0803) Business: Hematology Molecular target: Janus kinase-2 (JAK-2); …

    Published on 7/14/2014
  • Pyridorin pyridoxamine: Phase III started

    NephroGenex Inc. (NASDAQ:NRX), Research Triangle Park, N.C. Product: Pyridorin pyridoxamine Business: Renal Molecular target: Not available Description: Inhibitor of non-enzymatic glycoxidation leading to advanced …

    Published on 7/14/2014
  • Revolixys Kit: Phase III hold

    Regado Biosciences Inc. (NASDAQ:RGDO), Basking Ridge, N.J. Product: Revolixys Kit (formerly REG1 Anticoagulation System) Business: Cardiovascular Molecular target: NA Description: System composed of pegnivacogin (RB006…

    Published on 7/14/2014
  • RQ-00000004: Phase I started

    CJ Group, Seoul, South Korea RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Product: RQ-00000004 Business: Gastrointestinal Molecular target: H+/K ATPase pump Description: Potassium competitive acid pump antagonist …

    Published on 7/14/2014
  • SMT19969: Phase II started

    Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Product: SMT19969, SMT 19969 Business: Infectious Molecular target: NA Description: Oral, small molecule, heterocyclic antibiotic Indication: Treat Clostridium difficile-…

    Published on 7/14/2014
  • T-reg adoptive cell transfer: Phase I started

    Northwestern University, Evanston, Ill. Product: T-reg adoptive cell transfer (TRACT) Business: Transplant Molecular target: NA Description: Naturally occurring human regulatory T cells expanded ex vivo Indication: …

    Published on 7/14/2014
  • TC-6499: Phase I/II started

    Targacept Inc. (NASDAQ:TRGT), Winston-Salem, N.C. Product: TC-6499 Business: Gastrointestinal Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4); Nicotinic acetylcholine receptor alpha(4)beta(2) …

    Published on 7/14/2014
  • Translarna ataluren: Phase III started

    PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Product: Translarna ataluren (formerly PTC124) Business: Pulmonary Molecular target: Not available Description: Small molecule that facilitates complete …

    Published on 7/14/2014
  • Veliparib: Phase III started

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Veliparib (ABT-888) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Oral inhibitor of poly(ADP-ribose) polymerase (PARP) Indication: …

    Published on 7/14/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993